{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T18:13:10Z","timestamp":1790359990441,"version":"4.1.0"},"reference-count":33,"publisher":"American Society of Hematology","issue":"5","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2012,8,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>There are no data on the role of postconsolidation therapy with gemtuzumab ozogamicin (GO; Mylotarg) in children with acute myeloid leukemia (AML). The NOPHO-AML 2004 protocol studied postconsolidation randomization to GO or no further therapy. GO was administered at 5 mg\/m2 and repeated after 3 weeks. We randomized 120 patients; 59 to receive GO. Survival was analyzed on an intention-to-treat basis. The median follow-up for patients who were alive was 4.2 years. Children who received GO showed modest elevation of transaminase and bilirubin without signs of veno-occlusive disease. Severe neutropenia followed 95% and febrile neutropenia 40% of the GO courses. Only a moderate decline in platelet count and a minor decrease in hemoglobin occurred. Relapse occurred in 24 and 25 of those randomized to GO or no further therapy. The median time to relapse was 16 months versus 10 months (nonsignificant). The 5-year event-free survival and overall survival was 55% versus 51% and 74% versus 80% in those randomized to receive GO or no further therapy, respectively. Results were similar in all subgroups. In conclusion, GO therapy postconsolidation as given in this trial was well tolerated, showed a nonsignificant delay in time to relapse, but did not change the rate of relapse or survival (clinicaltrials.gov identifier NCT00476541).<\/jats:p>","DOI":"10.1182\/blood-2012-03-416701","type":"journal-article","created":{"date-parts":[[2012,6,23]],"date-time":"2012-06-23T04:21:08Z","timestamp":1340425268000},"page":"978-984","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":106,"title":["Gemtuzumab ozogamicin as postconsolidation therapy does not prevent relapse in children with AML: results from NOPHO-AML 2004"],"prefix":"10.1182","volume":"120","author":[{"given":"Henrik","family":"Hasle","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Aarhus University Hospital, Skejby, Denmark;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"Abrahamsson","sequence":"additional","affiliation":[{"name":"Institution for Clinical Sciences, Department of Pediatrics, Queen Silvia Children's Hospital, Gothenburg, Sweden;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Forestier","sequence":"additional","affiliation":[{"name":"Department of Medical Biosciences, Genetics, Ume\u00e5 University Hospital, Ume\u00e5, Sweden;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shau-Yin","family":"Ha","sequence":"additional","affiliation":[{"name":"Hong Kong Pediatric Hematology & Oncology Study Group, Department of Pediatrics, Queen Mary Hospital, Hong Kong, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesper","family":"Heldrup","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University Hospital, Lund, Sweden;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsi","family":"Jahnukainen","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University Central Hospital, Helsinki, Finland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d3lafur G\u00edsli","family":"J\u00f3nsson","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Landspitalinn, Reykjavik, Iceland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgitte","family":"Lausen","sequence":"additional","affiliation":[{"name":"Department of Pediatrics and Adolescent Medicine, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josefine","family":"Palle","sequence":"additional","affiliation":[{"name":"Department of Woman's and Children's Health, Uppsala University, Uppsala, Sweden; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernward","family":"Zeller","sequence":"additional","affiliation":[{"name":"Department of Pediatric Medicine, Oslo University Hospital, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"24","key":"2019111811275357200_B1","doi-asserted-by":"crossref","first-page":"4007","DOI":"10.1200\/JCO.2008.18.7948","article-title":"Risk-stratified therapy and the intensive use of cytarabine improves the outcome in childhood acute myeloid leukemia: the AML99 trial from the Japanese Childhood AML Cooperative Study Group.","volume":"27","author":"Tsukimoto","year":"2009","journal-title":"J Clin Oncol"},{"issue":"6","key":"2019111811275357200_B2","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S1470-2045(10)70090-5","article-title":"Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial.","volume":"11","author":"Rubnitz","year":"2010","journal-title":"Lancet Oncol"},{"issue":"3","key":"2019111811275357200_B3","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1200\/JCO.2010.30.6829","article-title":"Response-guided induction therapy in pediatric acute myeloid leukemia with excellent remission rate.","volume":"29","author":"Abrahamsson","year":"2011","journal-title":"J Clin Oncol"},{"issue":"3","key":"2019111811275357200_B4","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/j.1365-2141.2011.08851.x","article-title":"Results of a randomized trial in children with acute myeloid leukaemia: medical research council AML12 trial.","volume":"155","author":"Gibson","year":"2011","journal-title":"Br J Haematol"},{"issue":"6","key":"2019111811275357200_B5","first-page":"1490","article-title":"Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.","volume":"7","author":"Bross","year":"2001","journal-title":"Clin Cancer Res"},{"issue":"4","key":"2019111811275357200_B6","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1200\/JCO.2010.31.4310","article-title":"Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial.","volume":"29","author":"Burnett","year":"2011","journal-title":"J Clin Oncol"},{"issue":"3","key":"2019111811275357200_B7","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1002\/cncr.26190","article-title":"AAML03P1, a pilot study of the safety of gemtuzumab ozogamicin in combination with chemotherapy for newly diagnosed childhood acute myeloid leukemia: a report from the Children's Oncology Group.","volume":"118","author":"Cooper","year":"2012","journal-title":"Cancer"},{"issue":"1","key":"2019111811275357200_B8","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s11899-011-0103-0","article-title":"What happened to anti-CD33 therapy for acute myeloid leukemia?","volume":"7","author":"Jurcic","year":"2012","journal-title":"Curr Hematol Malig Rep"},{"issue":"4","key":"2019111811275357200_B9","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1182\/blood-2004-10-3821","article-title":"Safety and efficacy of gemtuzumab ozogamicin in pediatric patients with advanced CD33+ acute myeloid leukemia.","volume":"106","author":"Arceci","year":"2005","journal-title":"Blood"},{"issue":"4","key":"2019111811275357200_B10","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1111\/j.1365-2141.2008.07370.x","article-title":"Efficacy of fractionated gemtuzumab ozogamicin combined with cytarabine in advanced childhood myeloid leukaemia.","volume":"143","author":"Brethon","year":"2008","journal-title":"Br J Haematol"},{"issue":"5","key":"2019111811275357200_B11","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1111\/j.1365-2141.2009.08011.x","article-title":"Salvage treatment for children with refractory first or second relapse of acute myeloid leukaemia with gemtuzumab ozogamicin: results of a phase II study.","volume":"148","author":"Zwaan","year":"2010","journal-title":"Br J Haematol"},{"issue":"14","key":"2019111811275357200_B12","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1200\/JCO.2007.13.0096","article-title":"Safety and efficacy of gemtuzumab ozogamicin in combination with chemotherapy for pediatric acute myeloid leukemia: a report from the Children's Oncology Group.","volume":"26","author":"Aplenc","year":"2008","journal-title":"J Clin Oncol"},{"issue":"1","key":"2019111811275357200_B13","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/j.1365-2141.2010.08168.x","article-title":"Low-dose gemtuzumab-ozogamicin as post-consolidation therapy in elderly patients with acute myeloid leukaemia: a pilot study.","volume":"150","author":"Poloni","year":"2010","journal-title":"Br J Haematol"},{"issue":"13","key":"2019111811275357200_B14","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1182\/blood-2009-10-246470","article-title":"Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study.","volume":"115","author":"Lowenberg","year":"2010","journal-title":"Blood"},{"issue":"12","key":"2019111811275357200_B15","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1038\/sj.leu.2403962","article-title":"Long-term results in children with AML: NOPHO-AML Study Group\u2013report of three consecutive trials.","volume":"19","author":"Lie","year":"2005","journal-title":"Leukemia"},{"issue":"2","key":"2019111811275357200_B16","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/j.1365-2141.2006.06419.x","article-title":"Improved outcome after relapse in children with acute myeloid leukaemia.","volume":"136","author":"Abrahamsson","year":"2007","journal-title":"Br J Haematol"},{"issue":"8","key":"2019111811275357200_B17","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1038\/leu.2010.127","article-title":"Consequent and intensified relapse therapy improved survival in pediatric AML: results of relapse treatment in 379 patients of three consecutive AML-BFM trials.","volume":"24","author":"Sander","year":"2010","journal-title":"Leukemia"},{"issue":"12","key":"2019111811275357200_B18","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1038\/sj.leu.2403867","article-title":"Treatment of childhood acute myeloblastic leukemia: dose intensification improves outcome and maintenance therapy is of no benefit\u2013multicenter studies of the French LAME (Leucemie Aigue Myeloblastique Enfant) Cooperative Group.","volume":"19","author":"Perel","year":"2005","journal-title":"Leukemia"},{"issue":"11","key":"2019111811275357200_B19","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1200\/JCO.1994.12.11.2367","article-title":"Treatment of newly diagnosed children and adolescents with acute myeloid leukemia: a Childrens Cancer Group study.","volume":"12","author":"Wells","year":"1994","journal-title":"J Clin Oncol"},{"issue":"9825","key":"2019111811275357200_B20","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1016\/S0140-6736(12)60485-1","article-title":"Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study.","volume":"379","author":"Castaigne","year":"2012","journal-title":"Lancet"},{"issue":"16","key":"2019111811275357200_B21","doi-asserted-by":"crossref","first-page":"3705","DOI":"10.1182\/blood-2011-12-398370","article-title":"Correlation of CD33 expression level with disease characteristics and response to gemtuzumab ozogamicin containing chemotherapy in childhood AML.","volume":"119","author":"Pollard","year":"2012","journal-title":"Blood"},{"issue":"1","key":"2019111811275357200_B22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/cyto.b.20037","article-title":"Immunophenotypic differences between diagnosis and relapse in childhood AML: implications for MRD monitoring.","volume":"63","author":"Langebrake","year":"2005","journal-title":"Cytometry B Clin Cytom"},{"issue":"1","key":"2019111811275357200_B23","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/sj.leu.2401948","article-title":"Second malignancy after treatment of childhood acute myeloid leukemia.","volume":"15","author":"Leung","year":"2001","journal-title":"Leukemia"},{"issue":"7","key":"2019111811275357200_B24","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1002\/pbc.22931","article-title":"Quality of health in survivors of childhood acute myeloid leukemia treated with chemotherapy only: a NOPHO-AML study.","volume":"57","author":"Molgaard-Hansen","year":"2011","journal-title":"Pediatr Blood Cancer"},{"issue":"4","key":"2019111811275357200_B25","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1182\/blood-2007-09-114165","article-title":"Impaired CD163-mediated hemoglobin-scavenging and severe toxic symptoms in patients treated with gemtuzumab ozogamicin.","volume":"112","author":"Maniecki","year":"2008","journal-title":"Blood"},{"issue":"2","key":"2019111811275357200_B26","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1002\/1097-0142(20010715)92:2<406::AID-CNCR1336>3.0.CO;2-U","article-title":"Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation.","volume":"92","author":"Giles","year":"2001","journal-title":"Cancer"},{"issue":"1","key":"2019111811275357200_B27","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/sj.bmt.1703602","article-title":"Gemtuzumab ozogamicin (Mylotarg) monotherapy for relapsed AML after hematopoietic stem cell transplant: efficacy and incidence of hepatic veno-occlusive disease.","volume":"30","author":"Cohen","year":"2002","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"2019111811275357200_B28","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1182\/blood.V99.7.2310","article-title":"Hepatic sinusoidal obstruction after gemtuzumab ozogamicin (Mylotarg) therapy.","volume":"99","author":"Rajvanshi","year":"2002","journal-title":"Blood"},{"issue":"10","key":"2019111811275357200_B29","doi-asserted-by":"crossref","first-page":"3868","DOI":"10.1182\/blood-2002-07-1947","article-title":"Gemtuzumab ozogamicin: first clinical experiences in children with relapsed\/refractory acute myeloid leukemia treated on compassionate-use basis.","volume":"101","author":"Zwaan","year":"2003","journal-title":"Blood"},{"issue":"13","key":"2019111811275357200_B30","doi-asserted-by":"crossref","first-page":"4277","DOI":"10.1182\/blood-2003-05-1620","article-title":"A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia.","volume":"102","author":"Kell","year":"2003","journal-title":"Blood"},{"issue":"5","key":"2019111811275357200_B31","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.leukres.2006.07.005","article-title":"Gemtuzumab ozogamicin-associated sinusoidal obstructive syndrome (SOS): an overview from the research on adverse drug events and reports (RADAR) project.","volume":"31","author":"McKoy","year":"2007","journal-title":"Leuk Res"},{"issue":"1","key":"2019111811275357200_B32","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/bmt.2009.153","article-title":"Prior treatment with gemtuzumab ozogamicin and the risk of veno-occlusive disease after allogeneic haematopoietic stem cell transplantation.","volume":"45","author":"Chevallier","year":"2010","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"2019111811275357200_B33","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1038\/sj.leu.2403350","article-title":"High CD33-antigen loads in peripheral blood limit the efficacy of gemtuzumab ozogamicin (Mylotarg) treatment in acute myeloid leukemia patients.","volume":"18","author":"van der Velden","year":"2004","journal-title":"Leukemia"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/120\/5\/978\/1362709\/zh803112000978.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/120\/5\/978\/1362709\/zh803112000978.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,26]],"date-time":"2024-04-26T00:58:07Z","timestamp":1714093087000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/120\/5\/978\/30288\/Gemtuzumab-ozogamicin-as-postconsolidation-therapy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8,2]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012,8,2]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2012-03-416701","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,8,2]]}}}